Companies › Travere Therapeutics
2 active drug programs in 7 registered trials: 3 Phase 2, 2 Phase 3, 1 Phase 4, 1 Phase 1; Cardiovascular, Genitourinary, Metabolic and endocrine; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sparsentan Endothelin receptor ET-A antagonist; Type-1 angiotensin II receptor antagonist | EDNRA, AGTR1 | Phase 4 | Proteinuria; Immunoglobulin A Nephropathy; Focal Segmental Glomerulosclerosis; ANCA Associated Vasculitis | Mar 2027 |
| Pegtibatinase PEG-modified cystathionine beta-synthase (CBS) enzyme replacement | CBS | Phase 3 | Homocystinuria | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03762850 | Sparsentan | Phase 3 | Immunoglobulin A Nephropathy | Genitourinary | Aug 2023 |
| NCT05003986 | Sparsentan | Phase 2 | Focal Segmental Glomerulosclerosis | Genitourinary | Mar 2027 |
| NCT07219121 | Sparsentan | Phase 4 | Proteinuria | Genitourinary | Mar 2027 |
| NCT03406611 | Pegtibatinase | Phase 1 | Homocystinuria | Metabolic and endocrine | Jul 2027 |
| NCT06247085 | Pegtibatinase | Phase 3 | Homocystinuria | Metabolic and endocrine | Aug 2027 |
| NCT05630612 | Sparsentan | Phase 2 | ANCA Associated Vasculitis | Cardiovascular | Sep 2027 |
| NCT04663204 | Sparsentan | Phase 2 | Immunoglobulin A Nephropathy | Genitourinary | Dec 2027 |
Cash and short-term investments of $303m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Lexicon Pharmaceuticals RECORDATI GROUP Medicure Crystalys Therapeutics Kailera
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.